US equities
|
AAPL
$332.55
▼-1.71%
MU
$859.50
▲+3.11%
NVDA
$208.06
▲+2.97%
AMD
$487.83
▲+4.50%
SNDK
$1,128.42
▲+4.96%
ORCL
$124.14
▲+4.13%
PLTR
$169.94
▼-4.71%
SPCX
$140.68
▲+3.16%
AAPL
$332.55
▼-1.71%
MU
$859.50
▲+3.11%
NVDA
$208.06
▲+2.97%
AMD
$487.83
▲+4.50%
SNDK
$1,128.42
▲+4.96%
ORCL
$124.14
▲+4.13%
PLTR
$169.94
▼-4.71%
SPCX
$140.68
▲+3.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Theralase Technologies Inc
(OP:
TLTFF
)
0.1493
+0.0058 (+4.04%)
Delayed Quote
Updated: 9:57 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Theralase Technologies Inc
< Previous
1
2
3
4
Next >
Theralase Provides Bladder Cancer Clinical Study Update
October 26, 2026
Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the...
Via
Newsfile
Theralase(R) to Present at ThinkEquity Conference
October 09, 2026
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical...
Via
Newsfile
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
September 18, 2026
Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and...
Via
Newsfile
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
September 15, 2026
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Releases Q2 2026 Financial Statements
August 28, 2026
Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline
Via
Newsfile
Theralase(R) Grants Stock Options
August 07, 2026
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
August 04, 2026
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
June 30, 2026
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Lists Warrants on the TSXV
June 03, 2026
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Releases Q1 2026 Financial Statements
May 29, 2026
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
May 04, 2026
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
Via
Newsfile
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
April 13, 2026
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Closes $CAN 2.66 Million Financing
April 10, 2026
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
March 17, 2026
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
March 10, 2026
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
March 09, 2026
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical...
Via
Newsfile
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
February 20, 2026
This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.Toronto, Ontario--(Newsfile...
Via
Newsfile
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
↗
February 17, 2026
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
February 10, 2026
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Provides Update on Bladder Cancer Clinical Study
February 04, 2026
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
February 02, 2026
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
January 12, 2026
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with...
Via
Newsfile
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
December 23, 2025
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
December 12, 2025
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Investor Conference Call Reminder
November 17, 2025
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Releases 3Q2025 Financial Statements
November 10, 2025
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering...
Via
Newsfile
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
November 03, 2025
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
September 24, 2025
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Topics
Derivatives
Theralase(R) Extends Warrants
August 29, 2025
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
Theralase(R) Releases 2Q2025 Financial Statements
August 26, 2025
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...
Via
Newsfile
< Previous
1
2
3
4
Next >
